Document Detail


Effects of long-term ovariectomy and estrogen replacement on clonidine-evoked reductions in blood pressure and hemodynamic variability.
MedLine Citation:
PMID:  15071346     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The present study investigated the influence of 12-week ovariectomy (OVX) and estrogen supplementation (OVXE2) on the acute effects of the centrally acting antihypertensive agent clonidine on blood pressure, hemodynamic variability, and locomotor activity in Sprague-Dawley rats. The effects of estrogen depletion and repletion on the peripherally mediated hypotensive response to hydralazine were also evaluated to determine the selectivity of estrogen-clonidine interaction. The radiotelemetry technique was used for blood pressure and locomotor activity measurements. Three time-domain indices of hemodynamic variability were employed: (1). the standard deviation of mean arterial pressure (SDMAP) as a measure of blood pressure variability, and (2). the standard deviation of R-R intervals (SDRR) and the root mean square of successive differences in R-R intervals (rMSSD) as measures of heart rate variability. In control (sham-operated) rats, clonidine (30 microg/kg, i.p.) elicited significant decreases in MAP, blood pressure variability (SDMAP), and overall heart rate variability (SDRR). The reductions in MAP and its variability index (SDMAP) were significantly augmented in OVX rats and restored to sham-operated levels after estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/d, 12 weeks). The locomotor activity was reduced by clonidine only in OVX rats. In contrast to clonidine, hydralazine (0.5 mg/kg, i.p.) hypotension was not altered by OVX or estrogen replacement. These findings suggest that estrogen negatively modulates centrally evoked hypotension versus no effect on hypotension of peripheral origin. Further, the results implicate the cardiovascular autonomic control in the enhanced hypotensive response to clonidine in OVX rats.
Authors:
Mahmoud M El-Mas; Abdel A Abdel-Rahman
Related Documents :
11126256 - Respiratory depression under long-term sedation with sufentanil, midazolam and clonidin...
6380466 - Treatment of glaucoma using minidrops of clonidine.
9050986 - The use of moxonidine in the treatment of hypertension.
24671536 - Motor cortical dis-inhibition with baroreceptor unloading induced by orthostatic stress.
17178976 - Low-dose quadruple antihypertensive combination: more efficacious than individual agent...
3218896 - Sauna bather's circulation.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  43     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-04-08     Completed Date:  2004-12-22     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  607-15     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, School of Medicine, East Carolina University, Greenville, NC 27858, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antihypertensive Agents / pharmacology*
Blood Pressure / drug effects*
Clonidine / pharmacology*
Drug Interactions
Estradiol / pharmacology*
Estrogens / pharmacology*
Female
Heart Rate / drug effects*
Hydralazine / pharmacology
Motor Activity / drug effects
Ovariectomy
Rats
Rats, Sprague-Dawley
Time Factors
Grant Support
ID/Acronym/Agency:
AA07839/AA/NIAAA NIH HHS
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Estrogens; 4205-90-7/Clonidine; 50-28-2/Estradiol; 86-54-4/Hydralazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Continuing professional education: does it make a difference in perceived nursing practice?
Next Document:  Carvedilol inhibits basal and stimulated ACE production in human endothelial cells.